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Available online 11 February 2016The variable presentation and progression of Lennox–Gastaut syndrome (LGS) canmake it difﬁcult to recognize,
particularly in adults. To improve diagnosis, a retrospective chart review was conducted on patients who were
diagnosed as adults and/or were followed for several years after diagnosis. We present 5 cases that illustrate
changes in LGS features over time. Cases 1 and 2were diagnosed by age 8with intractable seizures, developmen-
tal delay, and abnormal EEGs with 1.5–2 Hz SSW discharges. However, seizure type and frequency changed over
time for both patients, and the incidence of SSWdischarges decreased. Cases 3, 4, and 5were diagnosedwith LGS
as adults based on current and past features and symptoms, including treatment-resistant seizures, cognitive and
motor impairment, and abnormal EEG ﬁndings.While incomplete, their records indicate that an earlier LGS diag-
nosis may have beenmissed or lost to history. These cases demonstrate the need to thoroughly and continuously
evaluate all aspects of a patient's encephalopathy, bearing in mind the potential for LGS features to change over
time.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Features1. Introduction
Lennox–Gastaut syndrome (LGS) is a severe, chronic epileptic en-
cephalopathy that presents during childhood. As one of the most difﬁ-
cult epileptic disorders to identify and manage, it accounts for up to
10% of childhood epilepsies [1]. It has been estimated that up to 25% of
LGS cases develop in previously healthy children for unknown reasons,
but most cases are associated with a congenital abnormality or insult to
the brain (e.g., injury, infection, and tumor) [1–3]. Seizures typically
begin before age 8, with a peak between 3 and 5 years of age [3].
Although onset after age 8 is rare, LGS has been diagnosed into
adolescence and adulthood [4–6]. The vastmajority of childrenwho de-
velop LGS will continue to exhibit at least some of its features into
adulthood.nox–Gastaut syndrome; SSW,
a),
ouris@bmc.org
vor.Resnick@mch.com
. This is an open access article underLennox–Gastaut syndrome has historically been characterized by
multiple intractable seizure types (tonic, atypical absence, and atonic
“drop attacks” that often result in falls), cognitive impairment or regres-
sion with associated loss of skills and behavioral problems (hyperactiv-
ity, aggression, and depression), and abnormal electroencephalogram
(EEG) ﬁndings of generalized 1.5–2.5 Hz slow spike–wave (SSW) com-
plexes [7–11]. Despite the identiﬁcation of these associated features,
LGS can be difﬁcult to diagnose because of the lack of speciﬁc biological
markers, multiple etiologies, and varied presentation of features at
onset [3,11,12]. In addition, the potential of features to evolve over
time further complicates the recognition of LGS, particularly in adults
[6,11–18].
To clarify and improve diagnosis in adults, we present 5 cases that il-
lustrate the evolution of LGS features and challenges in diagnosis.
2. Cases
2.1. Case 1 (M)
Case 1 was diagnosed with LGS at age 8 with intractable seizures,
cognitive and visual impairment, and EEG showing generalized 1.5–
2 Hz SSW discharges (Table 1 and Fig. 1, Panel A). Patient historythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of LGS features over time in case series.
Diagnosis
(age, yr)
F/U
(age, yr) Etiology Impairment
EEG findings Seizure typea
TreatmentsPrior Diagnosis F/U Prior Diagnosis F/U
CA
SE
 1
(M
)
8 12b Infection
Early: DD
Later: CI, VI
Right frontal and bi–
occipital spikes (6 wks);
hypsarrhythmia (6 mo)
SSW 1.5–2 Hz
Low–amplitude BA,
infrequent discharges,
infrequent MF sharp
waves
PMF, IS A, AA, T CP, T
Clonazepam, Lamotrigine,
Levetiracetam, Oxcarbazepine,
Phenobarbital, Rufinamide, Zonisamide
CA
SE
 2
(M
)
8 22 Unknown Early: DRAdult: profound CI NA SSW 1.5–2 Hz
Low–amplitude BA
infrequent discharges,
infrequent MF sharp
waves
P A, T A
Clonazepam, Phenobarbital
Current: Felbamate, Zonisamide
CA
SE
 3
(F
) 19 29 Unknown Early: mild DDAdult: mild CI SSW ≤1 Hz
High–amplitude
background slowing,
irregular high–amplitude
SW
Bursts of high–amplitude
slowing A, AA, TC A, TC A, TC
Carbamazepine, Clonazepam,
Felbamate, Lacosamide, Lamotrigine,
Phenobarbital, Phenytoin, Pregabalin,
Topiramate, Valproate, Zonisamide 
Current: Clobazam, Levetiracetam,
Rufinamide, VNS
CA
SE
 4
(F
) 28 30 IU Stroke Early: DD, left HPAdult: CI, depression Nonspecific slowing SSW 1–2 Hz NA IS, AA AA, TC
c None
ACTH, Carbamazepine, Divalproex,
Lamotrigine, Levetiracetam, Phenytoin,
Topiramate
Current: Clobazam, Rufinamide, VNS
CA
SE
 5
(F
) 32 43 Unknown
Early: DD, left HP
Adult:mild CI, ADD,
depression, behavior
problems
SW activity 4 Hz Bursts of atypical SWcomplexes 2–3 Hz NA FM, M, A
A, CP,
FM, SI None
Carbamazepine, Diazepam (rectal),
Gabapentin, Lamotrigine,
Levetiracetam, Oxcarbazepine,
Phenobarbital, Phenytoin, Pregabalin,
Primidone, Topiramate, Valproate,
Zonisamide, FL, OFR
Current: Clobazam, Rufinamide, VNS
ACTH indicates adrenocorticotropic hormone; BA, background activity; CI; cognitive impairment; DD, developmental delay; DR, developmental regression; F, female; FL, frontal lobecto-
my; F/U, follow-up; HP, hemiparesis; IU, intrauterine; M, male; mo, months; NA, information not available; None, the symptom or feature was not present; OFR, orbital frontal resection;
SSW, slow spike–wave discharges; SW, spike–wave discharges; VI, visual impairment; wks, weeks; and yr, year(s).
aSeizure types: A = atonic; AA= atypical absence; CP= complex partial; FM= focal motor; IS = infantile spasms; M=myoclonic; P = partial; PMF= partial multifocal; SI = startle-
induced; T = tonic; TC = tonic–clonic.
bSudden unexpected death occurred at age 12.
cSeizures occurred when patient discontinued seizure treatment due to acute depression.
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resulting in severe encephalomalacia. By 6 weeks of age, he had partial
multifocal seizures and EEG ﬁndings of right frontal and bioccipital
spikes and ictal discharges. By 7 months of age, he had infantile spasms
(IS) and possible hypsarrhythmia with global delay and visual impair-
ment. An EEG at 20 months showed right temporo–parietal spikes, left
occipital area attenuation, and slow occipital rhythm. By 3–4 years of
age, the patient had atonic, tonic, and atypical absence seizures, and
an EEG at age 6 showed multifocal spikes with generalized spike–
wave and polyspike–wave discharges.
Following LGS diagnosis at age 8 years, he had good but incomplete
control of complex partial and generalized tonic seizures. Prior to sud-
den unexpected death (SUDEP) at age 12 years, EEG showed low-
amplitude background activity, with infrequent low-amplitude general-
ized discharges and infrequent multifocal sharp waves (Fig. 1, Panel B).
Treatments included clonazepam, lamotrigine, levetiracetam,
oxcarbazepine, phenobarbital, ruﬁnamide, and zonisamide in various
combinations.
2.2. Case 2 (M)
Case 2 was diagnosedwith LGS at age 8 years with cognitive impair-
ment, tonic and atonic seizures, and abnormal EEG ﬁndings (Table 1).
Patient history included developmental regression and partial seizures
by 18 months of age, despite a normal birth and no history of brain in-
jury or infection. Fourteen years after his LGS diagnosis (age 22 years),
the patient could ambulate but had profound cognitive impairment
with minimal verbal communication. His EEG showed low-amplitude
background activity with infrequent low-amplitude generalized dis-
charges and infrequent multifocal sharp waves. Having failed previous
treatments including clonazepam and phenobarbital, his seizures were
mostly controlled (with brief atonic seizures a couple of times a day)
on felbamate and zonisamide.2.3. Case 3 (F)
Case 3 was diagnosed with LGS when she presented at age 19 years
withmild cognitive and speech impairment, seizureswith frequent falls
necessitating protective headgear, and abnormal EEG ﬁndings (Table 1
and Fig. 2, Panel A). Patient history was incomplete but included a nor-
mal birth followed by mild developmental delay and seizures of un-
known etiology (ﬁrst convulsive seizure was documented at age 9,
with prior staring episodes suspected). Later in childhood, she had
atypical absence, atonic, and tonic–clonic seizures. The EEG ﬁndings at
age 12 showed generalized background slowing and ≤1 Hz SSW dis-
charges (Fig. 2, Panel B). Treatments included carbamazepine, clonaze-
pam, felbamate, lacosamide, lamotrigine, phenobarbital, phenytoin,
pregabalin, topiramate, valproate, and zonisamide.
Six years after LGS diagnosis (age 25), EEG showed bursts of high-
amplitude background slowing, indicating a decrease or disappearance
of previously seen SSW discharges (Fig. 2, Panel C).
Ten years after diagnosis (age 29), seizure frequency had decreased
such that protective headgear was no longer needed with clobazam, le-
vetiracetam, ruﬁnamide, and VNS.2.4. Case 4 (F)
Case 4 was diagnosed with LGS when she presented at age 28 years
with seizures (atypical absence and tonic–clonic), depression, cognitive
impairment, mild left hemiparesis, and EEG ﬁndings of 1–2 Hz SSW
discharges (Table 1). Patient historywas incomplete but indicated intra-
uterine right hemispheric stroke with early left hemiparesis, IS,
developmental delay, and EEG ﬁndings at an unspeciﬁed age of
nonspeciﬁc slowing. Seizures had been mostly controlled with carba-
mazepine, divalproex, lamotrigine, phenytoin, or topiramate until
she became depressed and discontinued her medications at age 28
Fp1-AV
Fp2-AV
Fp3-AV
Fp4-AV
C3-AV
C4-AV
P3-AV
P4-AV
O1-AV
O2-AV
Space
F7-AV
F8-AV
T7-AV
T8-AV
P7-AV
P8-AV
Space
Fz-AV
Cz-AV
Pz-AV
EKG-A1A2
Space
EKG-Ref
Fp1-AV
Fp2-AV
Fp3-AV
Fp4-AV
C3-AV
C4-AV
P3-AV
P4-AV
O1-AV
O2-AV
Space
F7-AV
F8-AV
T7-AV
T8-AV
P7-AV
P8-AV
Space
Fz-AV
Cz-AV
Pz-AV
EKG-A1A2
Space
EKG-Ref
A
B
Fig. 1. Panel A. Case 1, age 8. EEG at LGS diagnosis, showing generalized 1.5–2 Hz SSWdischarges with frontal predominance, intermittent spike–waves predominating in the left occipital
region, and poorly formed posterior rhythm. Panel B. Case 1, age 12. EEG 4 years after diagnosis, showing low-amplitude background activity with infrequent low-amplitude generalized
discharges and infrequent multifocal sharp waves.
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seizure control with various treatment regimens (divalproex, levetirac-
etam, topiramate, and VNS), she is currently seizure-free on clobazam
and ruﬁnamide. She has intermittent problems with depression
but continues to live independently with regular checks from her
family.
2.5. Case 5 (F)
Case 5 was diagnosed with LGS at age 32 years when she presented
with abnormal EEG ﬁndings (Fig. 3), intractable seizures (predominantly
atonic but also complex partial, focal motor, and startle-induced), mild
cognitive and motor impairment, mild left hemiparesis, depression,
ADD, and behavioral issues. She was wheelchair-bound because of fre-
quent falls with injury from seizures. Her medical records were incom-
plete but included exaggerated startle response from birth and early
onset of seizures (unknown etiology), mild hemiparesis, and develop-
mental delay. By age 4, she had focal motor and myoclonic seizures and
EEGﬁndings of diffuse right hemisphere slowing and 4Hz SWdischarges.
She was diagnosed with epilepsy at age 7 and, by age 11, had learningproblems, psychological issues, and EEG ﬁndings with intermittent right
central–temporal slowing and bursts of SW activity. By age 19, she had
atonic seizures.
Previous treatments included carbamazepine, diazepam (rectal),
gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital,
phenytoin, pregabalin, primidone, topiramate, valproate, and zonisamide;
also VNS, frontal lobectomy, and orbital frontal resection. She is currently
seizure-free and has gone from using a wheelchair to a walker on a treat-
ment regimen of ruﬁnamide, clobazam, and VNS.
3. Discussion
Our cases illustrate the variable presentation and progression of LGS
features (Table 1) and demonstrate how this changing nature can com-
plicate diagnosis, particularly in adults who may not have complete re-
cords or for whom an earlier diagnosis may have beenmissed or lost to
history. Cases 1 and 2 (Sections 2.1 and 2.2) were diagnosed with LGS
in early childhood with intractable seizures, developmental delay, and
abnormal EEG ﬁndings with 1.5–2 Hz SSW complexes. In the years
following diagnosis, the frequency and type of seizure changed for
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Fig. 2. Panel A. Case 3, age 19. EEG at presentation and diagnosis, showing high-amplitude slowingwith irregular high-amplitude generalized SW discharges. Panel B. Case 3, age 12. EEG
7 years before diagnosis, showing generalized ≤1 Hz SSW discharges. Panel C. Case 3, age 25. EEG 6 years after diagnosis, showing bursts of high-amplitude background slowing.
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Fig. 3. Case 5, age 32. EEG at presentation and diagnosis, showing irregular posterior dominant 4–7 Hz rhythm and bursts of atypical 2–3 Hz SW complexes.
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disappeared.
Cases 3, 4, and 5 (Sections 2.3, 2.4, and 2.5)were diagnosed as adults
with treatment-resistant seizures, cognitive and/or motor impairment,
and abnormal EEG ﬁndings. Medical records for these patients were
incomplete but included developmental delay, childhood onset of mul-
tiple seizure types, and abnormal EEGs, indicating that an earlier diag-
nosis may have been missed or lost to history.
Similar to previous retrospective studies [12–19], our cases had
changes over time in seizure type/frequency and decreased incidence
of SSW discharges. These changes may reﬂect response to treatment
(i.e., medication effect), changes in brain plasticity during maturation,
effects on the brain of prolonged electrical or epileptic activity, and/or
sampling errors. The cases demonstrate the importance of continually
reappraising clinical and EEG features in patients with epileptic enceph-
alopathy and reevaluating therapeutic approaches and diagnoses. Given
the changing nature of its features and symptoms, LGS should be con-
sidered in all adult patients with treatment-resistant seizures and cog-
nitive impairment, especially those with a history of childhood onset
of multiple seizure types.
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